Upadacitinib hemihydrate
- Product Name
- Upadacitinib hemihydrate
- CAS No.
- 2050057-56-0
- Chemical Name
- Upadacitinib hemihydrate
- Synonyms
- Upadacitinib hemihydrate;ABT494 hemihydrate;ABT 494 hemihydrate;ABT-494 hemihydrate;Upadacitinib Hydrate;(3S,4R)-3-ethyl-4-(3H-imidazolo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate;Cinchonanium, 1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'- [[3-(trifluoromethyl)phenyllmethyl},bromide(1:2), (8a,9R)-";1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-
- CBNumber
- CB29872273
- Molecular Formula
- C17H21F3N6O2
- Formula Weight
- 398.39
- MOL File
- 2050057-56-0.mol
Upadacitinib hemihydrate Property
- InChI
- InChI=1/C17H19F3N6O.H2O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15;/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27);1H2/t10-,11+;/s3
- InChIKey
- VJSRYIXHEWRBKD-NFGOAHBONA-N
- SMILES
- C([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r|
Upadacitinib hemihydrate Chemical Properties,Usage,Production
Description
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA).
Clinical Use
Upadacitinib(RINVOQ) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Each prolonged-release tablet (RINVOQ 15 mg prolonged-release tablets.) contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
Side effects
The most common adverse effects with upadacitinib in the trials included urinary and upper respiratory tract infections, altered liver function and nausea. Rare but serious adverse events included malignancy, thrombosis and gastrointestinal perforation. As with other JAK inhibitors, serious and sometimes fatal infections can occur with upadacitinib – pneumonia and cellulitis were the most commonly reported in the trials. Opportunistic infections such as tuberculosis, multi-dermatomal herpes zoster, oral candidiasis, cryptococcosis and pneumocystosis have also occurred.
Upadacitinib hemihydrate Preparation Products And Raw materials
Raw materials
Preparation Products
Upadacitinib hemihydrate Suppliers
- Tel
- --
- Fax
- --
- mktg@pharmaffiliates.com
- Country
- India
- ProdList
- 6739
- Advantage
- 58
View Lastest Price from Upadacitinib hemihydrate manufacturers
- Product
- Upadacitinib hemihydrate 2050057-56-0
- Price
- US $0.00-0.00/G
- Min. Order
- 1G
- Purity
- 99%
- Supply Ability
- 1 ton/year
- Release date
- 2025-03-11
- Product
- Upadacitinib hemihydrate 2050057-56-0
- Price
- US $0.00-0.00/g
- Min. Order
- 50g
- Purity
- 99
- Supply Ability
- 10kgs
- Release date
- 2025-02-28
- Product
- Upadacitinib Hemihydrate 2050057-56-0
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-07-24